Making tuck-in acquisitions to bolster its injectables portfolio, as well as looking for deals that would add to its Specialty salesforce’s bag in central nervous system (CNS) indications such as neurology, is a priority for Amneal, even as the US-based player looks to pay off debt and finalize integration measures.
Discussing business-development priorities with investors, president and chief executive officer Rob Stewart insisted that “we still do have some firepower”...





